Last reviewed · How we verify
Omecamtiv Mecarbil Matrix F2 Formulation
At a glance
| Generic name | Omecamtiv Mecarbil Matrix F2 Formulation |
|---|---|
| Also known as | AMG 423, CK-1827452 |
| Sponsor | Cytokinetics |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omecamtiv Mecarbil Matrix F2 Formulation CI brief — competitive landscape report
- Omecamtiv Mecarbil Matrix F2 Formulation updates RSS · CI watch RSS
- Cytokinetics portfolio CI